Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/90| Cryptic transmission of SARS-CoV-2 in Washington State | |
| Truong N Nguyen Amanda Adler Elisabeth Brandstetter Shari Cho Danielle Giroux Peter D Han Kairsten Fay Chris D Frazar Lasata Shrestha Alexander L. Greninger Kirsten Lacombe Jover Lee Anahita Kiavand Matthew Richardson Thomas R Sibley Melissa Truong Caitlin R Wolf Deborah A Nickerson Misja Ilcisin Hong Xie Trevor Bedford Mark J Rieder Pavitra Roychoudhury the Seattle Flu Study Investigators Gregory L Armstrong Geoffrey S Baird Helen Y Chu Keith R Jerome Meei-Li Huang Arun Nalla Gregory Pepper Adam Reinhardt Duncan MacCannell Suxiang Tong Anna Uehara Michael Famulare James Hadfield Emma B Hodcroft John Huddleston Louise H Moncla Nicola F Müller Richard A Neher Xianding Deng Wei Gu Lea M Starita Scot Federman Charles Chiu Jeff Duchin Romesh Gautom Geoff Melly Brian Hiatt Philip Dykema Scott Lindquist Krista Queen Ying Tao Janet A Englund | |
| Novel Coronavirus | |
| Acceso Abierto | |
| Sin Derechos Reservados | |
| 10.1101/2020.04.02.20051417 | |
| Following its emergence in Wuhan, China, in late November or early December 2019, the SARS-CoV-2 virus has rapidly spread throughout the world. On March 11, 2020, the World Health Organization declared Coronavirus Disease 2019 (COVID-19) a pandemic. Genome sequencing of SARS-CoV-2 strains allows for the reconstruction of transmission history connecting these infections. Here, we analyze 346 SARS-CoV-2 genomes from samples collected between 20 February and 15 March 2020 from infected patients in Washington State, USA. We found that the large majority of SARS-CoV-2 infections sampled during this time frame appeared to have derived from a single introduction event into the state in late January or early February 2020 and subsequent local spread, strongly suggesting cryptic spread of COVID-19 during the months of January and February 2020, before active community surveillance was implemented. We estimate a common ancestor of this outbreak clade as occurring between 18 January and 9 February 2020. From genomic data, we estimate an exponential doubling between 2.4 and 5.1 days. These results highlight the need for large-scale community surveillance for SARS-CoV-2 introductions and spread and the power of pathogen genomics to inform epidemiological understanding. ### Competing Interest Statement Janet A. Englund is a consultant for Sanofi Pasteur and Meissa Vaccines, Inc., and receives research support from GlaxoSmithKline, AstraZeneca, and Novavax. Helen Chu is a consultant for Merck and GlaxoSmithKline. Jay Shendure is a consultant with Guardant Health, Maze Therapeutics, Camp4 Therapeutics, Nanostring, Phase Genomics, Adaptive Biotechnologies, and Stratos Genomics, and has a research collaboration with Illumina. Michael Famulare, Lea Starita, Pavitra Roychoudhury, Amanda Adler, Peter Han, Kirsten Lacombe, Elisabeth Brandstetter, Caitlin R. Wolf, Richard A Neher, James Hadfield, Nicola F. Müller, Jover Lee, Thomas Sibley, Kairsten Fay, Deborah A. Nickerson, Mark J. Rieder, and Trevor Bedford declare no competing interests. ### Funding Statement The Seattle Flu Study is run through the Brotman Baty Institute for Precision Medicine and funded by Gates Ventures, the private office of Bill Gates. The funder was not involved in the design of the study and does not have any ownership over the management and conduct of the study, the data, or the rights to publish. JS is an Investigator of the Howard Hughes Medical Institute. TB is a Pew Biomedical Scholar and is supported by NIH R35 GM119774-01. EBH and RAN are supported by University of Basel core funding. Sequencing analyses of SARS-CoV-2 genomes from California was supported by an NIH grant R33-AI129455 and the Charles and Helen Schwab Foundation to CYC, and an NIH grant K08-CA230156 and the Burroughs-Wellcome CAMS Award to WG. ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Consensus SARS-CoV-2 genome sequences were deposited into GISAID immediately on generation. They have been submitted to Genbank as well (accession pending). All data used in the paper is also available here: https://github.com/blab/ncov-cryptic-transmission. | |
| Cold Spring Harbor Laboratory Press | |
| 2020 | |
| Preimpreso | |
| https://www.medrxiv.org/content/10.1101/2020.04.02.20051417v1 | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| cryptic transmission.pdf | 788.99 kB | Adobe PDF | Visualizar/Abrir |